Adaptimmune Therapeutics (NASDAQ:ADAP) Research Coverage Started at StockNews.com
StockNews.com assumed coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Free Report) in a report issued on Wednesday. The firm issued a hold rating on the biotechnology company’s stock. ADAP has been the topic of a number of other research reports. Guggenheim decreased their price target on shares of Adaptimmune Therapeutics from $5.00 to $4.00 […]
More Stories
Small Plane Crashes Into New Hampshire Condominiums
By The Associated Press NASHUA, N.H.—A pilot was taken to the hospital with injuries Wednesday after a small plane crashed...
Meta Ordered to Provide User’s Complete Personal Data in Austrian Supreme Court Ruling
By Bill Pan Austria’s highest court has ordered Meta to give an online privacy activist full access to his personal...
6 More Fraud Suspects Indicted in Minnesota, as $18 Billion in Medicaid Billing Is Reviewed
By Janice Hisle U.S. First Assistant Attorney Joe Thompson announced indictments against a half-dozen new suspects in a pair of...
Trump Gives Federal Workers 2 More Days Off: Dec. 24 and 26
By Jackson Richman WASHINGTON—President Donald Trump signed an executive order on Thursday closing the federal government on Dec. 24 and...
Trump Media to Merge With Nuclear Fusion Company TAE in $6 Billion Deal
By Tom Ozimek President Donald Trump’s media company, Trump Media & Technology Group (TMTG), said on Dec. 18 that it...
Trump Announces $1,776 ‘Warrior Dividends’ to Military Members
By Jacob Burg President Donald Trump on Dec. 17 announced that more than a million military service members will receive...